Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accounts Payables: 2016-2024

Historic Accounts Payables for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $3.9 million.

  • Collegium Pharmaceutical's Accounts Payables rose 143.38% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 143.38%. This contributed to the annual value of $3.9 million for FY2024, which is 54.74% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Accounts Payables stood at $3.9 million for FY2024, which was down 54.74% from $8.7 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Accounts Payables high stood at $10.0 million for FY2020, and its period low was $3.5 million during FY2022.
  • Moreover, its 3-year median value for Accounts Payables was $3.9 million (2024), whereas its average is $5.4 million.
  • In the last 5 years, Collegium Pharmaceutical's Accounts Payables crashed by 58.18% in 2021 and then surged by 148.77% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Accounts Payables (Yearly) stood at $10.0 million in 2020, then slumped by 58.18% to $4.2 million in 2021, then dropped by 16.59% to $3.5 million in 2022, then spiked by 148.77% to $8.7 million in 2023, then slumped by 54.74% to $3.9 million in 2024.